Built-in Effort Tracking Streamlines Resource Allocation and Budgeting for Users of Allegro CTMS@Site
The summer release of Allegro [email protected]®, from Forte Research Systems, Inc., is full of new features that allow sites to operate more dynamically and efficiently. The clinical trial management system has new calendar options for managing staff time and expanded report choices. In addition, the summer release includes the feature of staff effort tracking.
The new functionality in Allegro [email protected] can help solve the problem of underestimating the number of hours staff spends on activities by allowing the site to track the staff time involved on any number of clinical trials, based on user-defined categories. Additionally, the staff management calendar feature grants selected site staff the opportunity to view schedules of other staff members from within the CTMS.
To set up a demonstration of Allegro [email protected] or to learn more, please contact Forte Research Systems.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
